Using genome-wide data from 253,288 individuals, we identified 697 variants at genome-wide significance that together explained one-fifth of the heritability for adult height. By testing different numbers of variants in independent studies, we show that the most strongly associated ~2,000, ~3,700 and ~9,500 SNPs explained ~21%, ~24% and ~29% of phenotypic variance. Furthermore, all common variants together captured 60% of heritability. The 697 variants clustered in 423 loci were enriched for genes, pathways and tissue types known to be involved in growth and together implicated genes and pathways not highlighted in earlier efforts, such as signaling by fibroblast growth factors, WNT/b-catenin and chondroitin sulfate-related genes. We identified several genes and pathways not previously connected with human skeletal growth, including mTOR, osteoglycin and binding of hyaluronic acid. Our results indicate a genetic architecture for human height that is characterized by a very large but finite number (thousands) of causal variants.
in GCTA 8 (Online Methods), which takes linkage disequilibrium (LD) between SNPs into account ( Supplementary Figs. 2 and 3, and Supplementary Table 1 ). The 697 SNPs clustered in 423 loci, with a locus defined as one or multiple jointly associated SNPs located within a 1-Mb window. Most of these 697 SNPs were uncorrelated, although those in close physical proximity (for example, <1 Mb apart) might be in partial LD (see Supplementary Table 1 for LD between adjacent pairs of the 697 SNPs). The clustering of signals was non-random (empirical enrichment of 1.4-fold; P < 1 × 10 −4 ) with 90, 26 and 31 loci containing 2, 3 and ≥4 signals, respectively ( Supplementary Tables 1  and 2 , and Supplementary Note). We observed strong evidence of clustering of association signals within loci across a range of locus sizes, from 100 kb to 1. 25 Mb, but the clustering was almost entirely driven by variants within 250 kb of index SNPs ( Supplementary Table 2 and Supplementary Note). In some loci, multiple signals clustered tightly around a single gene, whereas in other cases the clustering of associated variants was likely due to multiple different height-related genes being in close proximity ( Fig. 1 and Supplementary Fig. 4) .
Of the 697 SNPs, 403 were represented on the Metabochip array 9 . Using data from 80,067 individuals genotyped on the Metabochip array from 37 independent studies, we observed very strong evidence of concordance of effect sizes between the Metabochip and GWAS samples (P = 1.9 × 10 −160 ): >99% of variants had directionally consistent effects in the Metabochip and GWAS data (Online Methods, Supplementary Table 3 and Supplementary Note).
We observed a large genome-wide 'inflation' of the test statistic for association, even after we corrected each study's test statistics by its individual inflation factor (single λ GC = 1.94). At least two phenomena could have contributed to this observation. First, as described previously 10 , highly polygenic models of inheritance are expected to increase the genomic inflation factor to levels comparable to what we observe. Second, height is particularly susceptible to confounding by population ancestry (stratification), which can also lead to inflation Defining the role of common variation in the genomic and biological architecture of adult human height A full list of authors and affiliations appears at the end of the paper. Height is a classical polygenic trait that has provided general insights into the genetic architecture of common human traits and diseases and into the prospects and challenges of different methods used to identify genetic risk factors. Studies consistently estimate that the additive genetic contribution to normal variation in adult height ('narrow-sense heritability') is approximately 80% (refs. 1-3). Previous analysis of genome-wide association studies (GWAS) of adult height showed that common variants together account for 50% of this heritable contribution to variation in height 4, 5 . The most recent GWAS of adult height identified 180 loci, which together highlighted many genes relevant to human skeletal growth that had not been implicated in previous studies 6 . Common variants in these loci, however, only accounted for 10% of the phenotypic variation (~12% of heritability). Here we report the results from a GWAS meta-analysis of adult height in 253,288 individuals of European ancestry. We show that the additive contributions of fewer than 10,000 SNPs (at P < 5 × 10 −3 ) can account for 36% of the heritability of adult height. Variants reaching genome-wide significance (P < 5 × 10 −8 ) in this larger study (697 SNPs) clustered in loci, were substantially enriched for regulatory variants and implicated multiple known and previously unknown genes and pathways relevant to growth. More broadly, our results provide evidence that increasing GWAS sample sizes to the order of 10 5 individuals, now plausible for many common traits, will likely continue to identifying associated variants and loci while improving knowledge of the biology of these traits.
A r t i c l e s of the test statistics. We addressed these possibilities by comparing our results with those obtained using more stringent corrections for stratification (linear mixed models; LMMs) and with results obtained in subsets of studies in which a purely family-based analysis was feasible, and by performing a within-family prediction analysis that partitioned the variance in the genetic predictor into the contributions of true associations and population stratification.
Our LMM analyses, performed in a subset of 15 individual studies comprising 59,380 individuals, provided strong evidence that the inflated statistics were driven predominantly by the highly polygenic nature of the trait. This approach uses a genomic relationship matrix (GRM) calculated from genome-wide SNP data to correct for distant relatedness between all pairs of individuals in a study. We obtained a single λ GC of 1.20. This value is entirely consistent with the single λ GC of 1.20 obtained from the standard GWAS analysis of the same individuals and a single λ GC of 1.94 obtained from the analysis of all 253,288 individuals ( Supplementary Table 4 ). Because this approach might be overly conservative for a strongly genetic and highly polygenic trait, each study additionally repeated the analyses for each chromosome using a GRM generated from the remaining 21 chromosomes or, in the case of the largest study (WGHS), repeated the analyses for all odd-numbered chromosomes using a GRM generated from the even-numbered chromosomes and vice versa. The singleλ GC inflation factor for this analysis, 1.23, is also entirely consistent with the standard GWAS results (Online Methods, Supplementary  Table 4 and Supplementary Note).
Our family-based analyses also provided strong evidence that the inflated statistics were driven predominantly by the highly polygenic nature of height. We assessed whether variants that reached genome-wide significance after single-λ GC correction replicated in family-based analyses of up to 25,849 samples (effective sample size of 14,963; using methods that are immune to stratification (Online Methods, Supplementary Tables 5 and 6 , and Supplementary Note)). We identified genome-wide significant associations from a meta-analysis that excluded the family-based samples and tested these associations for replication in the family-based samples; a lower rate of replication than expected could be due to inflation of effect sizes in the discovery sample from 'winner's curse' and/or stratification. Of the 416 genome-wide significant SNPs representing multiple signals selected after the exclusion of the family-based studies, 371 SNPs had a consistent direction of effect (in comparison with 208 expected by chance and 400 expected in the absence of any inflation of estimated Figure 1 Regional association plots for loci with multiple association signals. (a-d) Examples of multiple signals after approximate conditional joint multiple-SNP (GCTA-COJO) analysis. SNPs are represented by colored symbols according to the index SNP with which they are in strongest LD (r 2 > 0.4). In some loci, the majority of signals cluster in and around a single gene, for example, at ACAN (a), ADAMTS17 (b) and PTCH1 (c), whereas at some loci multiple signals cluster through proximity (d).
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A r t i c l e s effect sizes) and 142 SNPs replicated with P < 0.05 (in comparison with 21 expected by chance and 210 expected in the absence of effect size inflation; Supplementary Table 5 ). These analyses (particularly the directional consistency) show that most of the loci represent true associations but also show that there is a modest inflation in the effect size estimates, due to stratification and/or winner's curse. To distinguish between these possibilities, we repeated this analysis, substituting for the family-based samples a random set of studies with similar total effective sample sizes. The number of replicating loci was only slightly lower in the family-based cohorts than in the random samples (12-17 fewer replications attributable to stratification at different P-value thresholds; Supplementary Table 5 ). This finding indicates that most of the modest inflation in effect estimates is due to winner's curse, that a small amount of inflation is due to residual stratification and that few (upper limit of ~15-25; Supplementary Table 5 and Supplementary Note) if any of the loci that reach genome-wide significance after single-λ GC correction are likely to be complete false positives due to stratification (that is, with no real association whatsoever with height).
Variance explained by SNPs at different significance levels
Having established that single-λ GC correction is sufficient to identify SNPs that are likely to be truly associated with height, we next performed a series of analyses using the GWAS data from five independent validation studies to quantify the fraction of phenotypic variance explained by SNPs selected from the GCTA-COJO analyses 7 of the meta-analysis data, which excluded data from the validation studies, at a range of statistical thresholds and to quantify the accuracy of predicting height using these selected SNPs (Online Methods). We first developed a new method that uses within-family prediction to partition the variance of the SNP-based predictor into components due to real SNP effects, errors in estimating SNP effects and population stratification (Online Methods), and we applied the method to data on full-sibling pairs from three of the five validation studies (Online Methods). Consistently across the three studies, all the partitioned variance components increased in size as a less stringent significance level was used for SNP selection in the discovery sample, and the error variance increased more dramatically than the genetic variance when more SNPs selected at a less significant level were included 
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A r t i c l e s in the predictor ( Fig. 2a-c) . We demonstrated the partitioning of variance due to population stratification by the within-family prediction analyses with and without adjusting for principal components (Supplementary Fig. 5 ). The results again confirmed that the impact of population stratification on the top associated SNPs was minor and demonstrated that the variation in the predictor due to true SNP effect, estimation error and population stratification was quantifiable. We next inferred, using these partitioned variance components from the within-family prediction analysis, how well different selected sets of SNPs would predict height in independent samples. We showed that the observed prediction accuracy (squared correlation between phenotype and predictor, or R 2 ) in five different population-based cohorts was highly consistent with the values inferred from the withinfamily analyses, with prediction accuracy peaking at ~17% using the ~1,900 SNPs reaching P < 5 × 10 −5 (Fig. 2d) . Finally, we estimated the variance explained by the selected SNPs in population-based studies using the GCTA-GREML method 4,8 ( Fig. 2e) . The results showed that ~670 SNPs at P < 5 × 10 −8 and ~9,500 SNPs at P < 5 × 10 −3 captured ~16% and ~29% of phenotypic variance, respectively (Table 1) , findings that were also consistent with the estimates inferred from the within-family prediction analysis. As shown in equation (19), prediction R 2 is not equal to the variance explained but is a function of the variance of true SNP effects and the error variance in estimating SNP effects, in the absence of population structure. At thresholds below genome-wide significance, the variance explained is higher than the prediction accuracy because the latter is deflated both by imprecise estimates of effect sizes (estimation errors) and the inclusion of SNPs that are not associated with height (Fig. 2) . The estimate of variance explained by all the HapMap 3 (ref. 11) SNPs without SNP selection was ~50% (Table 1) , consistent with previous estimates 4, 5 . Thus, a group of ~9,500 SNPs (representing <1% of common SNPs) selected at P < 5 × 10 −3 explained ~29% of phenotypic variance. Because ~50% of phenotypic variance is explained by all common SNPs the selected set of SNPs, despite being limited to <1% of common SNPs, accounts for the majority of the variance attributable to all common SNPs (29/50; ~60%). This set of ~9,500 SNPs strongly clustered with the newly established height loci: 1,704 (19%) variants were located within 250 kb of one of the 697 genome-wide associated SNPs, suggesting that a substantial fraction of 'missing heritability' is within already-identified loci. This clustering of additional variants within identified loci was confirmed in a parallel analysis based on two leftout studies where we observed that SNPs in closer physical proximity to the top associated SNPs explained disproportionally more variance (Online Methods and Supplementary Fig. 6 ).
The larger GWAS identifies new biologically relevant genes and pathways
Having shown that ~1% of variants can account for the majority of heritability attributable to common variation, we next considered whether the expanded set of height-associated variants could be used to identify the genomic features and biological pathways of most relevance to normal variation in adult height. To test whether our GWAS could implicate new biology, we used established and novel approaches to test whether the height-associated loci were enriched for functionally relevant variants, genes, pathways and tissues. Similar to the 180 variants identified in our previous analysis, the 697 variants were non-randomly distributed with respect to functional and putatively functional regions of the genome (Online Methods). We observed that the height-associated variants were enriched for nonsynonymous SNPs (empirical enrichment of 1.2-fold; P = 0.02), cis-regulatory effects in blood (empirical enrichment of 1.5-fold; P = 0.03), overlap with a curated list of genes that underlie monogenic syndromes of abnormal skeletal growth 12 (empirical enrichment of 1.4-fold; P = 0.013), associations with apparently unrelated complex traits in the National Human Genome Research Institute (NHGRI) GWAS catalog (empirical enrichment of 2.6-fold; P < 1 × 10 −4 ) and functional chromatin annotations in multiple tissues and cell types (empirical enrichment of 1.8-fold; P < 1 × 10 −3 ) ( Supplementary  Tables 7-11 and Supplementary Note).
The greater resolution for the height-associated variants provided by increased sample size, in combination with improved gene prioritization and gene set enrichment approaches, resulted in the identification of multiple new tissues, gene sets and specific genes that were highly likely to be involved in the biology of skeletal growth. Specifically, using a variety of established and novel pathway methods, we identified ~3 times as many enriched pathways and prioritized ~5 times as many genes (including genes newly prioritized in previously identified loci) in comparison to the results derived from identical pathway methods applied to the previous GWAS of 133,000 individuals ( Table 2) .
We first focused on existing pathway and gene prioritization methods: (i) MAGENTA 13 , a method designed to identify gene sets enriched in GWAS data, and (ii) GRAIL 14 , which uses the published literature to highlight connections between likely relevant genes within GWAS-identified loci. As expected, the GRAIL and MAGENTA analyses confirmed several previously identified gene sets and pathways clearly relevant to skeletal growth, but in the larger sample they also provided evidence for additional known and new SNPs were selected by an approximate conditional and joint multiple-SNP analysis (GCTA-COJO) of the summary statistics from the meta-analysis. The target cohort for variance estimation was excluded from the meta-analysis. h 2 , heritability; SE, standard error. Values in bold highlight the averages of five studies. a The estimates from all five cohorts were averaged by the inverse variance approach, where
The predicted variance explained by the selected SNPs (V g ) from the within-family prediction analysis. c SNPs from the HapMap 3 project 11 . npg A r t i c l e s associated genes, gene sets and protein complexes not identified in our previous smaller study (for example, fibroblast growth factor (FGF) signaling, WNT signaling, osteoglycin and other genes related to bone or cartilage development) ( Supplementary Fig. 7 and Supplementary  Tables 12 and 13) .
To obtain more detailed insight into height biology, we applied DEPICT, a novel data-driven, integrative method that uses gene sets reconstituted on the basis of large-scale expression data to prioritize genes and gene sets and also to identify tissues enriched in highly expressed genes from associated loci (T.H.P., J. Karjalainen, Y. Chan, H. Westra and A.R.W. et al., unpublished data; Online Methods and Supplementary Note). The DEPICT analysis highlighted 2,330 reconstituted gene sets (after pruning for high levels of redundancy). These gene sets both confirmed and extended the MAGENTA and GRAIL findings and identified new pathways not identified in our previous height GWAS (for example, regulation of β-catenin, biology related to glycosaminoglycans such as chondroitin sulfate and hyaluronic acid, and mTOR signaling) ( Supplementary Table 14 ). The gene sets identified on the basis of 327 strictly new height variants (>1 Mb from the 180 known variant loci) highly resembled the gene sets highlighted by the 180 already-known loci (Spearman's rank correlation coefficient between gene set enrichment z scores, r = 0.91; P = 2 × 10 −16 ). Thus, the variants discovered through increased sample size continued to highlight specific and relevant growth-associated gene sets, and the combined analysis of both old and new loci provided the additional power needed to identify new gene sets ( Table 3 and Supplementary Table 14 ).
The DEPICT analysis also prioritized tissues and individual genes. We found that genes within loci associated with height were enriched for expression in tissues related to chondrocytes (cartilage, joint capsule, synovial membrane and joints; P < 5.5 × 10 −9 , false discovery rate (FDR) < 0.001) and other musculoskeletal, cardiovascular and endocrine tissue types (FDR < 0.05) ( Fig. 3, Supplementary Fig. 8 and Supplementary Table 15 ). We also showed that a subset of the 697 height-associated SNPs that represented lead cis expression quantitative trait loci (eQTLs) in blood defined 75 genes that were collectively enriched for expression in cartilage (P = 0.008) ( Supplementary  Table 8 and Supplementary Note).
We used DEPICT to prioritize 649 genes (at FDR < 0.05) within height-associated loci ( Table 3 and Supplementary Table 16 ). Of these 649 genes, 202 genes (31%) were significant in the GRAIL analysis (Supplementary Tables 13 and 16 ) and/or overlapped with a list of genes involved in abnormal skeletal growth syndromes that we assembled from the Online Mendelian Inheritance in Man (OMIM) database 12 (n = 40; Supplementary Tables 9 and 16 ). Many other newly prioritized genes had additional supporting evidence ( Supplementary  Table 16 ), including specific expression in the growth plate 12 and/or connections to relevant pathways (for example: GLI2 and LAMA5 (Hedgehog signaling); FRS2 (FGF signaling); AXIN2, NFATC1, CTNNB1, FBXW11, WNT4, WNT5A and VANGL2 (WNT/β-catenin signaling); SMAD3 and MTOR (transforming growth factor (TGF)-β and/or mTOR signaling); WWP2-MIR140, IBSP, SHOX2 and SP3 (the corresponding genes are required in mice for proper bone and cartilage formation); CHSY1, DSE and PCOLCE2 (glycosaminoglycan/ collagen metabolism); and SCARA3, COPZ2, TBX18, CRISPLD1 and SLIT3 (differential expression in growth plate and predicted to be in highly relevant pathways)).
DEPICT also prioritized the genes that were new candidates for having a role in skeletal growth. The genes newly and strongly implicated in this study included not only genes with obvious relationships to skeletal biology, such as SOX5 and collagen genes, but also genes that have no clear published connection to skeletal growth and likely represent as-yet-unknown biology ( Table 3 and Supplementary  Table 16 ). DEPICT strongly prioritized genes that did not have published annotations related to growth pathways but were predicted to be in gene sets that were both enriched in the associated loci and clearly connected to growth. These included genes newly predicted to be in pathways related to cartilage or bone development (FAM101A, CRISPLD1 and the noncoding RNA LINC00476), collagen or extracellular matrix (GLT8D2, CCDC3 and ZCCHC24), histone demethylation (ATAD2B and TSTD2) and other genes predicted to have skeletal phenotypes but not currently annotated as belonging to relevant pathways (ARSJ, PSKH1, COPZ2, ADAMTS17 and the microRNA cluster MIR17HG). Of note, mutations in both ADAMTS17 and MIR17HG have been identified as causes of syndromic short stature in humans 15, 16 .
As suggested by the prioritization of ADAMTS17 and MIR17HG, it is possible that some of the newly highlighted genes might also underlie new syndromes of abnormal skeletal growth. As a further proof of principle, the second entry on our list of prioritized genes ( Table 3 and Supplementary Table 16 ), CHSY1, was not a known monogenic gene in the OMIM database 12 when we assembled our list, but mutations in this gene have since been shown to cause a syndrome including brachydactyly and short stature 17, 18 . Thus, the novel DEPICT method, applied to the larger GWAS data set, not only identified similar biology to GRAIL and MAGENTA but also implicated a large number of additional genes, gene sets and pathways that are likely important in skeletal biology and human growth. A r t i c l e s Growth factor binding (GO, P = 2.6 × 10 −14 ) Regulation of osteoblast differentiation (GO, P = 2.3 × 10 −11 ) WNT protein binding (GO, P = 1.9 × 10 −12 ) rs526896-rs9327705 The table lists 20 genes prioritized by DEPICT. Genes are ranked by the number of lines of supporting evidence and the DEPICT P value (supplementary table 16 ). Lines of supporting evidence for a gene included (1) annotation by GRAIL, (2) differential expression within the growth plate, (3) specific expression within the growth plate, (4) a mouse skeletal growth phenotype, (5) DEPICT FDR < 0.05, (6) membership in a DEPICT-prioritized gene set, (7) being the nearest gene to the lead SNP, (8) the lead SNP being an eQTL for the gene and (9) the lead SNP being a missense SNP for the gene. Because 20 of the 30 top-ranked genes were in a curated list of genes known to cause syndromes of abnormal skeletal growth 12 
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A r t i c l e s to common variants. As hypothesized by Yang et al. 5 , the heritability directly accounted for by variants identified by GWAS and inferred by whole-genome estimation approaches are converging with increasing sample size. The variance explained by genome-wide significant SNPs has increased from 3-5% with discovery samples of ~25,000 (ref. 19) to 10% with a discovery sample size of ~130,000 (ref. 6 ) and 16% with a discovery sample size of 250,000 (this study), and the variance explained from all captured common SNPs is ~50% (refs. 4,5) . The variance explained by genome-wide significant SNPs on a chromosome is also proportional to chromosome length, consistent with the conclusion made by Yang et al. 5 using all SNPs (Supplementary Fig. 9 ).
Our new results show that ~21%, ~24% and ~29% of phenotypic variance in independent validation samples is captured by the best ~2,000, ~3,700 and ~9,500 SNPs, respectively, selected in the discovery samples ( Table 1) , and that the correlation between actual and predicted height in independent samples from the same population has increased to 0.41 (maximum prediction R 2 = 0.41 2 = 0.17; Fig. 2d ).
The results are consistent with a genetic architecture for human height that is characterized by a very large but finite number (thousands) of causal variants, located throughout the genome but clustered in both a biological and genomic manner. Such a genetic architecture may be described as pseudo-infinitesimal and may characterize many other polygenic traits and diseases. There is also strong evidence of multiple alleles at the same locus segregating in the population and for associated loci overlapping with mendelian forms, suggesting a large but finite genomic mutational target for height and effect sizes ranging from minute (<1 mm; ~0.01 s.d.) to gigantic (>300 mm; >3 s.d.; in the case of monogenic mutations). It has been argued that the biological information emerging from GWAS will become less relevant as sample sizes increase because, as thousands of associated variants are discovered, the range of implicated genes and pathways will lose specificity and cover essentially the entire genome 20 . If this were the case, then increasing sample sizes would not help to prioritize follow-up studies aimed at identifying and understanding new biology and the associated loci would blanket the entire genome. Our study provides strong evidence to the contrary: the identification of many hundred and even thousand associated variants can continue to provide biologically relevant information. In other words, the variants identified in larger sample sizes both display a stronger enrichment for pathways clearly relevant to skeletal growth and prioritize many additional new and relevant genes. Furthermore, the associated variants are often non-randomly and tightly clustered (typically separated by <250 kb), resulting in the frequent presence of multiple associated variants in a locus. The observations that genes and especially pathways are now beginning to be implicated by multiple variants suggests that the larger set of results retain biological specificity but that, at some point, a new set of associated variants will largely highlight the same genes, pathways and biological mechanisms as have already been seen. This endpoint (which we have clearly not reached for height) could be considered analogous to reaching 'saturation' in model organism mutagenesis screens, where new alleles typically map to previously identified genes 21 .
We have identified a large number of gene sets and pathways that are enriched for associations with height. Although the number of gene sets and pathways is large, many overlap and likely represent multiple annotations of a much smaller set of core biological mechanisms. We also highlight individual genes within associated loci as being relevant to skeletal growth, including candidates that might contribute to syndromes of abnormal skeletal growth; for example, we strongly implicated CHSY1, recently identified as an underlying cause of a monogenic syndrome with short stature and brachydactyly 17, 18 .
The lists of prioritized genes and pathways should therefore provide a rich trove of data for future studies of skeletal growth; to facilitate such studies, we have made our results (including the genome-wide association results and the complete list of highlighted genes and pathways) publicly available. On the basis of the results of large genetic studies of height, we anticipate that increasing the number of associated loci for other traits and diseases could yield similarly rich lists that would generate new biological hypotheses and motivate future research into the basis of human biology and disease.
URLs. Genetic Investigation of Anthropometric Traits (GIANT) Consortium, http://www.broadinstitute.org/collaboration/giant/ index.php/GIANT_consortium; Mouse Genome Informatics, http:// www.informatics.jax.org/.
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A summary of the methods, together with a full description of genome-wide association analyses and follow-up analyses, can be found here and in the Supplementary Note. Written informed consent was obtained from every participant in each study, and the study was approved by relevant ethics committees.
Genome-wide association study meta-analysis. We combined the height summary association statistics from 79 GWAS in a meta-analysis of 253,288 individuals using the same methods and studies as previously described 6 and additional studies as described in Supplementary Tables 17-19 . Meta-analysis was performed on a total of 2,550,858 autosomal SNPs using the inverse variance fixed-effects method with METAL 22 .
GCTA-COJO: conditional and joint multiple-SNP analysis. We used GCTA-COJO analysis 7, 8 to select the top associated SNPs. This method uses the summary statistics from the meta-analysis and LD correlations between SNPs estimated from a reference sample to perform a conditional association analysis 7 . The method starts with an initial model of the SNP that shows the strongest evidence of association across the whole genome. It then implements the association analysis conditioning on the selected SNP(s) to search for the top SNPs iteratively one by one via a stepwise model selection procedure until no SNP has a conditional P value that passes the significance level. Finally, all the selected SNPs are fitted jointly in the model for effect size estimation. We used 6,654 unrelated individuals from the ARIC cohort as the reference sample for LD estimation. There were ~3.0 million SNPs included in the original meta-analysis. We included in this analysis only the SNPs (~2.48 million) in HapMap 2 for which we had a sample size of >50,000. We used the genomewide significance level P < 5 × 10 −8 (as reported in Supplementary Table 1 ).
Metabochip replication.
We combined the height summary association statistics from 37 independent studies genotyped using the Illumina Metabochip array 9 in a meta-analysis of 80,067 individuals of European ancestry (Supplementary Tables 20-22 ). Each study tested the association for each genotyped SNP using the same quality control procedures, height transformation, adjustment and inheritance model as described for the GWAS analysis. Genomic control correction was applied to the results for each study before meta-analysis, using a set of 4,427 SNPs associated with QT interval to control study-specific inflation factors. We used the inverse variance fixed-effects meta-analysis method.
Validation: linear mixed model-based association analysis. Each of 15 studies (59,380 individuals) used genome-wide SNP information to calculate a GRM for all pairs of individuals and used this matrix to correct association statistics for cryptic relatedness and population stratification. Each study used an LMM as implemented in the software EMMAX 23 . Meta-analysis was performed as described for the standard GWAS using a single-λ GC correction. Each study additionally repeated the analyses for each chromosome using a GRM generated from the remaining 21 chromosomes or, in the case of the largest study (WGHS), repeated the analysis for all odd-numbered chromosomes using a GRM generated from the even-numbered chromosomes and vice versa. Each study then combined the association results from the 22 or 2 parts of the genome into a single set of data, and the single-λ GC meta-analysis was repeated.
Validation: within-family (transmission) association analyses.
A pure transmission-based analysis was performed in 7 cohorts for SNPs representing 416 signals of association (Supplementary Note), selected after repeating metaanalysis excluding these studies with single-λ GC correction. The filtering out of SNPs with low imputation quality in the studies was followed by applying the inverse variance method of meta-analysis to the family-based results. Because of the presence of related individuals, family-based studies have lower power at a given sample size. For each study, we calculated the effective sample size (the size of a sample of unrelated individuals that would have equivalent power; see the Supplementary Note and Winkler et al. 24 ). Estimation of winner's curse in our data set was performed by repeating the meta-analysis excluding either the family-based studies or random sets of studies from GIANT matched by effective sample size to the family-based studies. Independent genome-wide significant loci were selected from each meta-analysis. Power for replication in the excluded samples was estimated at different P-value thresholds, and the deficit in replication (number of replications expected minus the number observed replications) was calculated. The contribution of winner's curse to the deficit in replication was estimated as the average deficit across the three sets of random non-family-based cohorts. By subtracting this deficit from the deficit observed for the family-based cohorts, we estimated the lack of replication that could be attributed to stratification (either inflation of effect size for true associations or false positive associations).
Variance and heritability explained. We used GCTA-COJO analysis to select the top associated SNPs at a range of stringent significance levels (5 × 10 −3 , 5 × 10 −4 , 5 × 10 −5 , …, 5 × 10 −8 ) for estimation and prediction analyses. We then quantified the variance explained by the selected SNPs using a threestage analysis-within-family prediction, GCTA-GREML analysis and population-based prediction-in five validation studies (B-PROOF, FRAM, QIMR, TwinGene and WTCCC-T2D). To avoid sample overlap, we repeated the main GWAS meta-analysis and the multiple-SNP analysis five times, each time excluding one of the five validation studies. This approach ensured complete independence between the data used to discover SNPs and the data used to estimate how much variance in height these SNPs explained and how well they predicted height. For the within-family prediction analyses, we selected 1,622, 2,758 and 1,597 pairs of full siblings from the QIMR, TwinGene and FRAM cohorts, respectively, with 1 sibling pair per family. For the whole-genome estimation and prediction analyses, we used GCTA-GRM 8 to estimate the genetic relatedness between individuals and selected unrelated individuals with pairwise genetic relatedness of <0.025 in each of the 5 studies: B-PROOF (n = 2,555), FRAM (n = 1,145), QIMR (n = 3,627), TwinGene (n = 5,668) and WTCCC-T2D (n = 1,914).
Within-family prediction analysis. We used the SNPs selected from GCTA-COJO analysis to create a genetic predictor (also called a 'genetic profile score') for each of the full-sibling pairs using PLINK 25 . We then adjusted the genetic predictor by the first 20 principal components generated from principalcomponent analysis (PCA) 26 . By comparing the predictors within and between families, we partitioned the variance in the predictor analysis into components due to real SNP effects (V g ), errors in estimating SNP effect (V e ) and population structure (C g + C e ).
We calculated the weighted average of each of the four (co)variance components over the three cohorts by their sample size:
with the subscript i indicating the cohort and n indicating the sample size. From the results of these partitioning analyses within families, we can infer what the prediction R 2 value (equation (19)) and what the proportion of the variance explained by SNPs (V g /V p , with V p being the phenotypic variance) would be in a sample of unrelated individuals when using the same set of SNPs. We then tested these inferred values in unrelated samples.
GCTA-GREML analysis.
We performed GREML analysis 4 in GCTA 8 to estimate the variance explained by the selected SNPs (h g 2 ) in each of the five validation studies. This method fits the effects of a set of SNPs simultaneously in a model as random effects and estimates the genetic variance captured by all the fitted SNPs without testing the significance of the association of any single SNPs. We combined the estimates of h g 2 from the five studies by the inverse variance approach:
Population-based prediction analysis. We created a genetic predictor using the selected SNPs for the unrelated individuals in each of the five validation studies. We then calculated the squared correlation (R 2 ) between the phenotype and predictor in each validation study and calculated the average prediction R 2 value weighted by the sample size across the five studies:
Theory and method to partition the variance in a genetic predictor. Under the assumption of an additive genetic model, the phenotype of a quantitative trait can be written as:
where y is the trait phenotype, g is the total genetic effect of all SNPs, x is an indicator variable for SNP genotypes, b is the SNP effect and ε is the residual. From this model, the additive genetic variance is: with the first component being the expected value of additive genetic variance under linkage equilibrium (LE) and the second component being deviation from the expected value that could be caused by LD, population structure or selection 27 .
Considering a pair of full siblings in a family, the additive genetic covariance between the siblings is: If we take a set of SNPs with their effects estimated from GCTA-COJO analysis and create a predictor using these SNPs in an independent validation sample, we can write the predictor as:ˆĝ
where b is the estimate of b, with b b e = + where e is the error in estimating b.
If we assume b and e to be independent and denote V x e i i e = ∑ var( ) 2
(1) (1)
(2) (2)
(4) The covariance between the true phenotype and the predictor for the same individual is:ˆc ov( ,ˆ) cov( , ) var( ) a y g g g g V C = + + = = + e e g g
The covariance between the true phenotype of one sibling and the predictor of the other sibling is: where V g can be interpreted as the variance explained by real SNP effects, C g is the covariance between predictors attributed to the real effects of SNPs that are not in LD but are correlated owing to population stratification, V e is the accumulated variance due to errors in estimating SNP effects and C e is the covariance between predictors attributed to errors in estimating the effects of SNPs that are correlated owing to population stratification.
To assess prediction accuracy, we usually perform a regression analysis of the real phenotype against the predictor:â 
